Company: NIVFW
Filing Date: 2025-05-20
Form Type: F-1/A
Source: 0001213900-25-045737
Chunk: 188

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-20
Form: F-1/A
Chunk 188
---
 the Company approved a reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value and preferred shares with no par value, at an exchange ratio of one (1) share for ten (10) shares (the “Reverse Stock Split”). Upon the opening of the market on May 5, 2025, the Company’s Class A Ordinary Shares began trading on the Nasdaq Capital Market (“Nasdaq”) on a post-Reverse Stock Split basis.

In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.

Revenue recognition

The Company adopted ASC Topic 606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC 606 on April 1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic 606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (“IVF”) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:

| (1) | identify its contracts with customers;                                                                                                                                                                                                                  |
| (2) | identify its performance obligations under those contracts;                                                                                                                                                                                             |
| (3) | determine the transaction prices of those contracts;                                                                                                                                                                                                    |
| (4) | allocate the transaction prices to its performance obligations in those contracts; and                                                                                                                                                                  |
| (5) | recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services. |

The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.

The Company derives its revenues
from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization (“IVF”)